Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $271.6 million.

  • Stoke Therapeutics' Liabilities and Shareholders Equity rose 22.82% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 37.56%. This contributed to the annual value of $271.6 million for FY2024, which is 18.92% up from last year.
  • Per Stoke Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $271.6 million for FY2024, which was up 18.92% from $228.3 million recorded in FY2023.
  • Stoke Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $271.6 million during FY2024, with a 5-year trough of $228.3 million in FY2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $252.0 million, with a median of $256.1 million in 2022.
  • In the last 5 years, Stoke Therapeutics' Liabilities and Shareholders Equity fell by 10.83% in 2023 and then grew by 18.92% in 2024.
  • Stoke Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $256.1 million in 2022, then declined by 10.83% to $228.3 million in 2023, then climbed by 18.92% to $271.6 million in 2024.